Several previous meta-analyses have indicated a significantly increased risk of FAEs associated with anti-VEGFR agents in solid tumors,[54–56] but the risk of FAEs with these agents in advanced NSCLC remains undetermined. The gene discussed is KDR; the disease is non-small cell lung carcinoma.